 Rubius Therapeutics Inc NASDAQ: RUBY has announced updated data from the ongoing monotherapy Phase 1 arm of the Phase 12 trial of RTX-240 in advanced solid tumors. Data were shared at the American Association for Cancer Research Annual Meeting. 